Radiological impact of the use of calcium hydroxylapatite dermal fillers.
OBJECTIVE
To report a case series in which the radiological features of the subcutaneous use of calcium hydroxylapatite (CaHa) dermal fillers are described for the first time.


METHODS
Five patients with facial hyperattenuating hypermetabolic subcutaneous lesions were identified on 2- [(18)F]-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography/computed tomography (PET/CT), who gave a history of facial injections to augment physical appearance. Correlation with additional imaging studies was performed.


RESULTS
All cases had subcutaneous high attenuation material on CT (range 280-700HU), which was FDG avid on PET, with a standardized uptake value (SUV) range of 2.9-13.4. Magnetic resonance imaging (MRI) demonstrated a heterogeneous intermediate signal intensity subcutaneous lesion with enhancement post-gadolinium in one case.


CONCLUSIONS
CaHa dermal filler is hyperattenuating on CT, hypermetabolic on FDG-PET imaging, of intermediate signal intensity on MRI, and is a potential cause of a false-positive imaging study.
Feeney
J N
JN
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. jnfeeney@hotmail.com
Fox
J J
JJ
Akhurst
T
T
D000328:Adult; D000368:Aged; D001672:Biocompatible Materials / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003357:Cosmetic Techniques; D017886:Durapatite / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005145:Face / Q000000981:diagnostic imaging; D005189:False Positive Reactions; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007279:Injections, Subcutaneous; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D019651:Plastic Surgery Procedures; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed; D055815:Young Adult
D001672:Biocompatible Materials; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D017886:Durapatite